Carry-over in pre-dose samples for steady state BE [Study As­sess­ment]

posted by hirenpharm – Ahmedabad, 2019-03-29 20:56  – Posting: # 20103
Views: 685

Hello everyone,

We did a multiple dose (5 weeks, 1 TDS patch every week) bioequivalence study. The BE was assessed at week 5 at steady state. It was a 3-period study. In period 2 and 3, we observed some carry-over from the previous period treatments. I remember, the 5% of Cmax rule for single-dose studies. But, can someone please throw some light on how to handle this carry-over in multiple dose steady state studies? Does the carry-over in week 1 pre-dose really impact week 5 steady state parameters? any regulatory guidance/published articles will be really helpful.

Edit: Category changed; see also this post #1[Helmut]

Dr. Hiren Mehta

Complete thread:

 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,537 posts in 4,144 threads, 1,338 registered users;
online 6 (0 registered, 6 guests [including 5 identified bots]).
Forum time (Europe/Vienna): 17:34 CEST

When puzzled, it never hurts to read the primary documents –
a rather simple and self-evident principle that has, nonetheless,
completely disappeared from large sectors
of the American experience.    Stephen Jay Gould

BEBAC Ing. Helmut Schütz